Dr. Zhenyu Pan, MD, PhD, is currently working as Director of the Department of Radiation Oncology at Huizhou Hospital Affiliated to Guangzhou Medical University in China. Having received his MD and PhD degrees from Jilin University in 2008 and 2019, respectively. In June 2008, Dr. Pan commenced his employment at the Cancer Center of the First Hospital of Jilin University. In February 2023, he transitioned to the Radiotherapy Oncology Department of Huizhou Hospital Affiliated to Guangzhou Medical University as a disciplinary leader. His focus is on the comprehensive diagnosis, treatment, and molecular mechanism research of head, neck, and central nervous system tumors. He conducted the first prospective study internationally on intrathecal chemotherapy and concurrent radiotherapy for leptomeningeal metastasis (2010-2014, ChiCTR-OOC-14005403), which confirmed for the first time that leptomeningeal metastasis patients with adverse prognostic factors can receive effective treatment (Int J Cancer, 2016). Following that, he conducted the first prospective clinical studies of phase I (2017-2018, Clinical Trials: NCT03101579) and phase I/II (2018-2019, Clinical Trials: NCT03507244) of intrathecal pemetrexed for leptomeningeal metastasis internationally. The recommended dose and treatment plan for intrathecal administration of pemetrexed have been determined, making it the sixth chemotherapy agent that can be used for intrathecal administration in human beings (Front Oncol, 2019; Then Adv Med Oncol, 2020). He has published more than 30 articles as the first (responsible) author. The research results have been presented and reported at the Asian and European Annual Conference on Neurology; Additionally, he has delivered more than 20 speeches and reports at authoritative domestic conferences such as the Meeting of the European Association of Neuro-Oncology, the meeting of the Asian Society for Neuro-Oncology, the Annual Meeting of Chinese Society of Clinical Oncology, the Annual Meeting of China Society for Radiation Oncology, and the Annual Meeting of Chinese Symposium on Medical Oncology, and has won the Excellent Paper Award multiple times.